IL1B and inflammatory bowel disease: Additionally, nanoparticles have shown significant promise in targeting the NLRP3 inflammasome, an intracellular complex that drives the release of pro-inflammatory cytokines such as IL-1β and IL-18 (Xu and Nunez, 2023), marking it as an emerging target in IBD therapy.